Rezolute reports Q1 EPS (22c), consensus (33c)

Reports Cash, cash equivalents and investments in marketable securities were $117.8M as of September 30, , compared to $127.1M as of June 30 ..”Execution across our two Phase 3 programs in patients with congenital HI and tumor HI will be the focus going into 2025,” said Nevan Elam, Chief Executive Officer and Founder of Rezolute (RZLT). “We are pleased with the progress we’ve made in sunRIZE enrollment and look forward to advancing our Phase 3 study in tumor HI patients based on the success demonstrated in our Expanded Access Program. As a rare disease company with two late-stage clinical trials, we recognize how critical 2025 will be in progressing our programs in order to provide a potentially meaningful therapy for patients where limited options currently exist.”